Patents Assigned to Xencor
  • Heterodimeric antibodies that bind somatostatin receptor 2
    Patent number: 11225521
    Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: January 18, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, Sung-Hyung Lee, Paul Foster
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11225528
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: January 18, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210395363
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 23, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc variants with altered binding to FcRn
    Patent number: 11198739
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: December 14, 2021
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11111315
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Modulation of T cells with bispecific antibodies and Fc fusions
    Patent number: 11091548
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 17, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Seung Chu, Dilki Wickramarachichi, John Desjarlais
  • Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
    Patent number: 11084863
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 10, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
  • Optimized antibody variable regions
    Patent number: 11053316
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 6, 2021
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
    Patent number: 10981992
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 20, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Heterodimeric antibodies that bind fibroblast activation protein
    Patent number: 10982006
    Abstract: The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: April 20, 2021
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Alex Nisthal, Seung Chu
  • Optimized anti-CD3 variable regions
    Patent number: 10968276
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 6, 2021
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10913803
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 9, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210009689
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 14, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210009690
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10889653
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 12, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric proteins
    Patent number: 10858417
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Bispecific antibodies that bind to CD38 and CD3
    Patent number: 10858451
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Y. Chu, Gregory Moore, John Desjarlais
  • Heterodimeric human IgG1 polypeptides with isoelectric point modifications
    Patent number: 10851178
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: December 1, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20200317804
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: April 1, 2020
    Publication date: October 8, 2020
    Applicant: XENCOR, INC.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
    Patent number: 10793632
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 6, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon